Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359579 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function
A Phase 1 study, sponsored by Anthera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01359579 is a Phase 1 study that was terminated before completion, run by Anthera Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT01359579, a Phase 1 study, was terminated before completion, sponsored by Anthera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of varespladib methyl in mild or moderate renal impairment patients and healthy volunteers.
Interventions
- DRUG varespladib methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359579
The ClinicalTrials.gov registry entry for NCT01359579 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which varespladib methyl is the first listed.
NCT01359579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359579 about?
NCT01359579 is a clinical study titled "A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function". The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of varespladib methyl in mild or moderate renal impairment patients and healthy volunteers.
What is the current status of trial NCT01359579?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01359579?
The interventions under investigation include: varespladib methyl (DRUG).
Who is sponsoring clinical trial NCT01359579?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.